BACTI B Stock Overview
A medical device company, provides infection prevention solutions in orthopedics, urology, intravascular/critical care, dental, and wound care therapeutic areas in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Bactiguard Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr69.40 |
| 52 Week High | kr95.00 |
| 52 Week Low | kr49.50 |
| Beta | -0.21 |
| 1 Month Change | 1.76% |
| 3 Month Change | -2.25% |
| 1 Year Change | -9.75% |
| 3 Year Change | -64.19% |
| 5 Year Change | 73.93% |
| Change since IPO | 120.32% |
Recent News & Updates
Recent updates
Bactiguard Holding AB (publ)'s (STO:BACTI B) 30% Share Price Surge Not Quite Adding Up
Feb 06
Bactiguard Holding (STO:BACTI B) Is Carrying A Fair Bit Of Debt
Jan 12Is Bactiguard Holding (STO:BACTI B) Using Debt In A Risky Way?
Jul 02Bactiguard Holding AB (publ)'s (STO:BACTI B) Business Is Trailing The Industry But Its Shares Aren't
May 05Bactiguard Holding (STO:BACTI B) Has Debt But No Earnings; Should You Worry?
Feb 15Does Bactiguard Holding (STO:BACTI B) Have A Healthy Balance Sheet?
Sep 15Is Bactiguard Holding (STO:BACTI B) Using Debt Sensibly?
Jun 03Does Bactiguard Holding (STO:BACTI B) Have A Healthy Balance Sheet?
Jan 22Is Bactiguard Holding (STO:BACTI B) Using Too Much Debt?
Feb 26Do Institutions Own Bactiguard Holding AB (publ) (STO:BACTI B) Shares?
Jan 22Did Bactiguard Holding AB (publ) (STO:BACTI B) Insiders Buy Up More Shares?
Dec 27Bactiguard Holding (STO:BACTI B) Has A Pretty Healthy Balance Sheet
Nov 22
Shareholder Returns
| BACTI B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -2.3% | 0.5% | 0.9% |
| 1Y | -9.8% | -6.9% | 19.0% |
Return vs Industry: BACTI B underperformed the Swedish Medical Equipment industry which returned -6.9% over the past year.
Return vs Market: BACTI B underperformed the Swedish Market which returned 19% over the past year.
Price Volatility
| BACTI B volatility | |
|---|---|
| BACTI B Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: BACTI B's share price has been volatile over the past 3 months.
Volatility Over Time: BACTI B's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 191 | Christine Lind | www.bactiguard.com |
Bactiguard Holding AB (publ), a medical device company, provides infection prevention solutions in orthopedics, urology, intravascular/critical care, dental, and wound care therapeutic areas in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company's infection prevention solutions reduce the risk of infections and the use of antibiotics. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter, which reduces the risk of catheter related bloodstream infection and antibiotics; BIP Endotracheal Tube, that reduces the ventilator associated pneumonia, antibiotics, and healthcare costs; BIP Endotracheal Tube Evac, a tube that combines the subglottic secretion drainage with coating to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that offers surveillance and infection prevention.
Bactiguard Holding AB (publ) Fundamentals Summary
| BACTI B fundamental statistics | |
|---|---|
| Market cap | kr2.43b |
| Earnings (TTM) | -kr126.18m |
| Revenue (TTM) | kr201.62m |
12.1x
P/S Ratio-19.3x
P/E RatioIs BACTI B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BACTI B income statement (TTM) | |
|---|---|
| Revenue | kr201.62m |
| Cost of Revenue | kr46.51m |
| Gross Profit | kr155.11m |
| Other Expenses | kr281.30m |
| Earnings | -kr126.18m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 16, 2024
| Earnings per share (EPS) | -3.60 |
| Gross Margin | 76.93% |
| Net Profit Margin | -62.58% |
| Debt/Equity Ratio | 50.9% |
How did BACTI B perform over the long term?
See historical performance and comparison